JP7174982B2 - アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用 - Google Patents

アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用 Download PDF

Info

Publication number
JP7174982B2
JP7174982B2 JP2017564426A JP2017564426A JP7174982B2 JP 7174982 B2 JP7174982 B2 JP 7174982B2 JP 2017564426 A JP2017564426 A JP 2017564426A JP 2017564426 A JP2017564426 A JP 2017564426A JP 7174982 B2 JP7174982 B2 JP 7174982B2
Authority
JP
Japan
Prior art keywords
compound
bone
pharmaceutically acceptable
acid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017564426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519277A (ja
JP2018519277A5 (enExample
Inventor
マリオン テヴナン
ロバート エヌ ヤング
ガン チェン
Original Assignee
サイモン フレイザー ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイモン フレイザー ユニヴァーシティー filed Critical サイモン フレイザー ユニヴァーシティー
Publication of JP2018519277A publication Critical patent/JP2018519277A/ja
Publication of JP2018519277A5 publication Critical patent/JP2018519277A5/ja
Application granted granted Critical
Publication of JP7174982B2 publication Critical patent/JP7174982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017564426A 2015-06-12 2016-06-13 アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用 Active JP7174982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562175118P 2015-06-12 2015-06-12
US62/175,118 2015-06-12
PCT/IB2016/053482 WO2016199111A1 (en) 2015-06-12 2016-06-13 Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2018519277A JP2018519277A (ja) 2018-07-19
JP2018519277A5 JP2018519277A5 (enExample) 2020-04-30
JP7174982B2 true JP7174982B2 (ja) 2022-11-18

Family

ID=57503230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564426A Active JP7174982B2 (ja) 2015-06-12 2016-06-13 アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用

Country Status (5)

Country Link
US (2) US10400000B2 (enExample)
EP (1) EP3307747A4 (enExample)
JP (1) JP7174982B2 (enExample)
CN (1) CN107849072B (enExample)
WO (1) WO2016199111A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
US20250295725A1 (en) * 2022-01-14 2025-09-25 Purdue Research Foundation Bone targeted treatment in osteogenesis imperfecta
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds
WO2026013441A1 (en) * 2024-07-10 2026-01-15 Mesentech Inc. Bisphosphonate-ep4 agonists for selective delivery to damaged muscle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532491A (ja) 2006-04-04 2009-09-10 アラーガン インコーポレイテッド プロスタグランジンｅｐ４作用薬
JP2013531627A (ja) 2010-05-28 2013-08-08 サイモン フレイザー ユニバーシティ プロスタグランジンビスホスホネート結合体化合物およびその作製方法ならびにその使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224995A (en) * 1961-02-16 1965-12-21 Ethyl Corp Polyvinyl chloride plasticized with dialkoxyalkyl homoterephthalates
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JPS6034971A (ja) * 1984-07-23 1985-02-22 Sangyo Kagaku Kenkyu Kyokai 抗菌性組成物
DE3827836C1 (enExample) 1988-08-17 1989-10-19 Eduard Kuesters, Maschinenfabrik, Gmbh & Co Kg, 4150 Krefeld, De
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (enExample) 1993-08-25 1995-09-21 Merck & Co Inc
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
US6121253A (en) 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
WO2003047417A2 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
EP1513589B1 (en) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
CA2487977A1 (en) 2002-06-06 2003-12-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
JP2006504679A (ja) 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
US7560589B2 (en) 2003-07-28 2009-07-14 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
JP2010513551A (ja) 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物
WO2012102355A1 (ja) * 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2014078446A2 (en) 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532491A (ja) 2006-04-04 2009-09-10 アラーガン インコーポレイテッド プロスタグランジンｅｐ４作用薬
JP2013531627A (ja) 2010-05-28 2013-08-08 サイモン フレイザー ユニバーシティ プロスタグランジンビスホスホネート結合体化合物およびその作製方法ならびにその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2015年，26(6)，p.1095-1103
Bioorganic & Medicinal Chemistry，20(6)，2012年，p.2131-2140
Journal of Bone and Mineral Research，2015年，30(4)，p.670-680

Also Published As

Publication number Publication date
CN107849072B (zh) 2020-12-15
JP2018519277A (ja) 2018-07-19
WO2016199111A1 (en) 2016-12-15
EP3307747A1 (en) 2018-04-18
US11312737B2 (en) 2022-04-26
US20190345179A1 (en) 2019-11-14
US10400000B2 (en) 2019-09-03
EP3307747A4 (en) 2019-02-27
US20180170951A1 (en) 2018-06-21
CN107849072A (zh) 2018-03-27
CA2988523A1 (en) 2016-12-15
NZ738016A (en) 2024-10-25

Similar Documents

Publication Publication Date Title
US11312737B2 (en) Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
US5409911A (en) Prostaglandin analog for treating osteoporosis
JP6082692B2 (ja) プロスタグランジンビスホスホネート結合体化合物およびその作製方法ならびにその使用
US7285572B2 (en) CaSR antagonist
EP1131327B1 (en) Prostaglandin conjugates for treating or preventing bone diseases
JP2015057388A (ja) Ｓ１ｐ受容体モジュレーターおよびそれらの使用
EA036098B1 (ru) Способ получения противогрибковых соединений
KR20110013411A (ko) (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법
JP2017512777A (ja) 抗真菌化合物の調製方法
Tanaka et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
US8324378B2 (en) Prodrugs and conjugates of prenylation inhibitors
US20250263428A2 (en) Amide-linked conjugate compounds and uses thereof
KR101327635B1 (ko) 포스폰산화 리파마이신, 및 그의 뼈 및 관절 감염의 저지및 치료 용도
US9650414B1 (en) Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CA3003741A1 (en) Bortezomib conjugates and methods using same
CA2988523C (en) Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
US11672811B2 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms
HK1250987A1 (en) Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
KR20080028358A (ko) 포스폰산화 플루오로퀴놀론, 그의 항박테리아 유사체, 및뼈 및 관절 감염의 저지 및 치료 방법
HK1250987B (en) Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
US7638505B2 (en) Organophosphoric derivatives useful as anti-parasitic agents
CZ20003445A3 (cs) Alifatické aminokarboxylové a aminofosfonové kyseliny, aminonitrily a aminotetrazoly jako buněčná záchranná činidla

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210924

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211129

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221031

R150 Certificate of patent or registration of utility model

Ref document number: 7174982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250